SPR 1
Alternative Names: SPR-1; SPR1-0117; SPR1-TE-0294Latest Information Update: 26 Jun 2024
Price :
$50 *
At a glance
- Originator Sporos BioDiscovery
- Class Antineoplastics; Small molecules
- Mechanism of Action TEA domain transcription factor inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 05 Apr 2024 Pharmacodynamics and adverse events data from a preclinical study in Solid tumours presented at the 115th Annual Meeting of the American Association for Cancer Research (AACR-2024)
- 17 Apr 2023 Pharmacodynamics and adverse events data from a preclinical study in Solid tumours presented at the Annual Meeting of American Association for Cancer Research (AACR-2023)
- 15 Mar 2023 Pharmacodynamics data from a preclinical study in Solid tumours released by Sporos BioDiscovery